Amani Thomas Mori's picture

Amani Thomas Mori

Postdoctoral Fellow, Centre for International Health
  • E-mailAmani.Mori@uib.no
  • Phone+47 944 33 988
  • Visitor Address
    Alrek helseklynge, blokk D, Årstadveien 17
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2021). Do household perceptions influence enrolment decisions into community-based health insurance schemes in Tanzania? BMC Health Services Research. 11 pages.
  • Show author(s) (2019). The cost-effectiveness of incentive-based active case finding for tuberculosis (TB) control in the private sector Karachi, Pakistan. BMC Health Services Research.
  • Show author(s) (2017). Cost-benefit and extended cost-effectiveness analysis of a comprehensive adolescent pregnancy prevention program in Zambia: study protocol for a cluster randomized controlled trial. Trials. 1-10.
  • Show author(s) (2016). Equity impact analysis of medical approaches to cardiovascular diseases prevention in Tanzania. Social Science and Medicine. 208-217.
  • Show author(s) (2016). Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: A Markov modelling study. BMC Health Services Research.
  • Show author(s) (2016). Budget impact analysis of using dihydroartemisinin–piperaquine to treat uncomplicated malaria in children in Tanzania. PharmacoEconomics (Auckland). 303-314.
  • Show author(s) (2014). The role of evidence in the decision-making process of selecting essential medicines in developing countries: the case of Tanzania. PLOS ONE. 10 pages.
  • Show author(s) (2014). Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malaria Journal.
  • Show author(s) (2013). Role of pharmacoeconomics in developing countries. Farmeconomia. Health economics and therapeutic pathways. 3-5.
  • Show author(s) (2013). Reforms: a quest for efficiency or an opportunity for vested interests'? a case study of pharmaceutical policy reforms in Tanzania. BMC Public Health. 6 pages.
  • Show author(s) (2012). Priority setting for the implementation of artemisinin-based combination therapy policy in Tanzania: evaluation against the accountability for reasonableness framework. Implementation Science. 8 pages.
  • Show author(s) (2019). Farmasøyter med og uten genser: Hvordan farmasiutdanningene i Bergen og Dar es Salaam blir bedre av et nord-sør samarbeid .
Academic lecture
  • Show author(s) (2018). Post-discharge risks of morbidity and mortality in children in malaria endemic settings in Africa: A systematic review and meta-analysis - Oral presentation.
  • Show author(s) (2018). Post-discharge Malaria Chemoprevention for Children Under the Age of 5 years in Africa.
Doctoral dissertation
  • Show author(s) (2015). Pharmacoeconomics and Formulary Decision-Making in Tanzania. Generating Evidence for Antimalarial Drugs.
Academic literature review
  • Show author(s) (2020). Patient and health system costs of managing pregnancy and birth-related complications in sub-Saharan Africa: A systematic review. Health Economics Review. 1-15.
  • Show author(s) (2018). Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: A retrospective review of data from the regulatory authority. BMJ Open. 1-7.
  • Show author(s) (2012). Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review. BMC Medical Informatics and Decision Making. 9 pages.

More information in national current research information system (CRIStin)